DelMar Pharma to Raise $8 Million in Private Placement

DelMar Pharma, a Vancouver-Menlo Park drug developer with significant ties to China, announced plans to raise up to $8 million in a secondary offering. Two weeks ago, the company reported positive data from an early-stage trial of VAL-083 in patients with gliobastoma multiforme. DelMar sources VAL-083 from Guangxi Wuzhou Pharma in China, where it is approved to treat leukemia and lung cancer. DelMar owns China rights to the drug for the glioblastoma multiforme indication. More details.... Stock Symbol: (OTC: DMPI) Share this with colleagues: // //